Who’s going to be flying high in the cell and gene therapy niche and why?

It’s time to switch horses and start thinking about cell therapies again…

Essentially what we have on deck today is a bakers dozen i.e. thirteen different categories exploring the future of gene therapy and cell therapy approaches and how they might make an impact in the medium term future.

There will likely be many others coming along too – something we plan to write about from the upcoming ASGCT meeting next month.

If we take stock there’s plenty of cool or innovative ideas already being explored or about to make a splash, including one company many BSB readers may not have heard about plus a new biotech company coming out of stealth mode… who are they and what are they all about?

To learn more about gene and cell therapy improvements in the oncology niche and get a heads up on our oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by